Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $138,571.86 in Stock

Posted by Geri Gentry on Jun 16th, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) Director Ra Capital Management, L.P. bought 15,414 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were bought at an average cost of $8.99 per share, with a total value of $138,571.86. Following the transaction, the director directly owned 16,638,150 shares of the company’s stock, valued at approximately $149,576,968.50. This trade represents a 0.09% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.89 per share, with a total value of $1,110,298.77.
On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.57 per share, with a total value of $3,351,032.83.
On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.91 per share, with a total value of $4,339,267.80.
On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.00 per share, with a total value of $721.00.
On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $6.91 per share, with a total value of $3,310,159.49.
On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Trading Down 2.9%

Artiva Biotherapeutics stock traded down $0.27 during trading hours on Tuesday, reaching $8.91. 780,946 shares of the company were exchanged, compared to its average volume of 355,699. The firm has a market cap of $220.26 million, a price-to-earnings ratio of -2.52 and a beta of 2.40. The stock has a 50-day moving average of $8.98 and a 200 day moving average of $6.20. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

ARTV has been the subject of several research reports. Wedbush increased their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. HC Wainwright increased their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.00.

Get Our Latest Research Report on Artiva Biotherapeutics

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ARTV. Citadel Advisors LLC lifted its position in Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after purchasing an additional 644,658 shares during the period. BNP Paribas Financial Markets lifted its position in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the period. Marshall Wace LLP bought a new position in Artiva Biotherapeutics in the fourth quarter worth $341,000. Jane Street Group LLC bought a new position in Artiva Biotherapeutics in the second quarter worth $67,000. Finally, Landscape Capital Management L.L.C. bought a new position in Artiva Biotherapeutics in the third quarter worth $112,000.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.